FDA Class I Recall Issued for Abiomed Automated Impella Controllers Over Hardware Issues

Johnson & Johnson’s Abiomed has issued another safety correction involving Automated Impella Controllers, the devices used to control and monitor Impella heart pumps in critically ill cardiac patients. The U.S. Food and Drug Administration has identified the correction as a Class I recall, the agency’s most serious recall classification.

According to the FDA, the recall affects certain Automated Impella Controllers that require hardware updates to address potential safety concerns. These controllers serve as the primary user interface for Impella catheters, allowing physicians and hospital staff to monitor pump performance, respond to alarms, and assess catheter positioning.

The concern is straightforward and serious: if the controller fails to boot properly or suddenly interrupts support, a patient relying on the Impella system may experience a delay or loss of hemodynamic support. For medically fragile patients, even a temporary interruption in circulatory support can create significant risks.

What Problems Were Identified With the Impella Controllers?

Abiomed identified several hardware-related issues during a retrospective review of servicing records. The FDA notice describes four potential problems requiring hardware updates:

• The internal video graphics array cable may be positioned too close to a digital signal processor chipset, creating a risk of electrostatic discharge that could interrupt motor controls.
• The compact flash memory card may become dislodged, potentially causing startup failures or data-logging problems.
• Improper fan wire routing may damage the wire and lead to console boot-up failure.
• Capacitor-related issues on the power battery manager may contribute to pump stoppage, purge stoppage, or fan fuse failures.

To address these issues, Abiomed’s servicing team is implementing several hardware fixes, including cable retention devices, flash memory card retainers, wire clips, and updated circuit board components.

The FDA warned that all four issues could result in a controller failing to boot or a sudden interruption in hemodynamic support. In those situations, clinicians may need to exchange the controller for a replacement device, further delaying treatment.

Why This Recall Matters

Impella heart pumps are used in high-risk cardiac situations, including cardiogenic shock and certain complex heart procedures. These patients are often already unstable and may be highly dependent on the pump for circulatory support.

When a device intended to support the heart malfunctions, the margin for error can be extremely narrow. A delay or loss of hemodynamic support may increase the risk of serious injury or death, depending on the patient’s condition and level of dependence on the device.

The FDA stated that hospital inventory may continue to be used while affected products are corrected. Abiomed has instructed facilities to work with its servicing team to coordinate the necessary hardware changes and to forward the recall notice to anyone responsible for managing, storing, transporting, stocking, or using the affected devices.

A Broader Pattern of Impella Safety Concerns

This latest correction comes after a series of recalls and safety alerts involving Impella pumps and controllers in recent years. In May 2026, the FDA also issued an early alert regarding a separate Automated Impella Controller issue involving a software error that may cause the controller to restart while used with left ventricular Impella devices.

In that separate alert, the FDA reported that the pump may stop for approximately 35 seconds during a restart, leaving the patient unsupported by the Impella system. As of April 27, Abiomed had reported two serious injuries and one death associated with that software-related issue.

While the latest hardware correction has not been linked to reported serious injuries or deaths as of the FDA’s notice, the continued stream of Impella-related corrections raises important patient safety questions about device design, servicing, warnings, and hospital risk management.

What Patients and Families Should Do

Patients and families may not know whether an Impella controller was used during a hospitalization or cardiac procedure. These devices are typically used in hospital settings by medical professionals, and the controller itself may not be something a patient ever sees or recognizes.

Anyone who suffered a serious cardiac complication, loss of circulatory support, unexpected deterioration, stroke, organ injury, or death involving Impella therapy may want to request and preserve the relevant medical records. Important records may include operative reports, ICU notes, device logs, nursing notes, adverse event documentation, and discharge summaries.

Families should also ask whether an Impella device or Automated Impella Controller was used, whether any device alarms or controller malfunctions occurred, and whether the hospital received any recall or correction notices involving the equipment.

Parker Waichman LLP Is Reviewing Impella Heart Pump Injury Claims

Parker Waichman LLP is reviewing potential claims involving serious injuries and deaths associated with Impella heart pumps and Automated Impella Controllers. Medical device manufacturers have a responsibility to design safe products, provide adequate warnings, and act quickly when safety issues are identified.

If you or a loved one suffered serious complications after Impella heart pump treatment, you may have legal rights. Contact Parker Waichman LLP today for a free, confidential case review.